Systemic lupus erythematosus (SLE) is a complex, prototypic, systemic autoimmune disease of great interest to the Autoimmunity Center of Excellence network. However, by the time patients receive the devastating SLE diagnosis, the majority have ongoing aggressive inflammatory processes and oftentimes damage that cannot be reversed. Once these autoimmune cascades are underway, dissecting the basic concepts of disease initiation, perpetuation and direct pathogenesis from the complications of end-organ damage can be quite difficult. Our Oklahoma ACE builds on unique populations and experimental systems to address early events in systemic autoimmunity. Few repositories exist that allow researchers to investigate SLE development before clinical manifestations. Through our collaboration with the US Department of Defense, we have identified 240 patients who developed SLE while serving in the US military and who had serum samples that were provided before SLE classification. We previously obtained serial samples from the DoDSR for 130 of these patients, as well as four matched controls for each patient. Initial studies with these samples found that autoantibodies precede clinical illness by many years, that the Sm and Ro (alone) systems begin by targeting a single antigenic structure then become progressively more complicated and that a few autoantibodies are detectable before their associated clinical manifestations. In addition, we now have in house the samples from an additional 100 SLE patients and their matched controls and are seeking ACE funding to examine temporal associations of key targetable pathways in the pre-clinical stages to support or refute rationale use of interventions directed against interferon alpha or vitamin D supplementation for SLE patients. Further elucidation of the etiology and early pathogenesis of SLE will also provide improved biomarkers regarding select aspects of autoantibodies that correlate with onset of clinical disease features, and identify autoantibody subsets that help predict disease and allow identification of """"""""high risk"""""""" populations for potential interventional trials.
Our specific aims will address the following key clinical questions: 1) Does vitamin D deficiency precede lupus autoimmunity and/or clinical disease onset? 2) Does an increase in interferon activity occur before or concurrently with the onset of lupus autoimmunity or clinical disease? 3) Does non-specific autoimmunity precede onset of lupus-specific autoimmunity and thereby serve as a predictor of disease? 4) Does autoantibody concentration, specificity or affinity change with symptom onset and can these changes help direct therapeutic decisions?

Public Health Relevance

Understanding the initial targets and pre-clinical features of SLE will provide the basis for the development of lupus-specific diagnostic tests, evaluation of candidate pathways to target for SLE therapies, assessment of temporal associations to examine surrogates of causation for select biomarkers, and the determination of patients with the highest likelihood of response to specific therapies and for recruitment to potential prevention trials.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-QV-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oklahoma Medical Research Foundation
Oklahoma City
United States
Zip Code
Munroe, Melissa E; Vista, Evan S; Merrill, Joan T et al. (2017) Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun 78:70-78
Arriens, Cristina; Wren, Jonathan D; Munroe, Melissa E et al. (2017) Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford) 56:i32-i45
Aberle, Teresa; Bourn, Rebecka L; Chen, Hua et al. (2017) Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus Sci Med 4:e000176
Langefeld, Carl D; Ainsworth, Hannah C; Cunninghame Graham, Deborah S et al. (2017) Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun 8:16021
Munroe, Melissa E; Young, Kendra A; Kamen, Diane L et al. (2017) Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis Rheumatol 69:630-642
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2017) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol :
Jog, Neelakshi R; James, Judith A (2017) Biomarkers in connective tissue diseases. J Allergy Clin Immunol 140:1473-1483
Merrill, Joan T; Immermann, Fred; Whitley, Maryann et al. (2017) The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol 69:1257-1266
Young, Kendra A; Munroe, Melissa E; Guthridge, Joel M et al. (2017) Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann Rheum Dis 76:153-158
Sandhya, Pulukool; Kurien, Biji Theyilamannil; Danda, Debashish et al. (2017) Update on Pathogenesis of Sjogren's Syndrome. Curr Rheumatol Rev 13:5-22

Showing the most recent 10 out of 116 publications